Dr. C. Ola Landgren - Ash 2024

Dr. C. Ola Landgren - ASH 2024

Sylvester Comprehensive Cancer Center

Dr. C. Ola Landgren - ASCO 2024

Sylvester Comprehensive Cancer Center

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

MPE webinar: ASH 2024 myeloma and AL amyloidosis highlights

Myeloma Patients Europe

HealthTree Podcast for Multiple Myeloma: Dr. C. Ola Landgren, NCI

HealthTree Foundation for Multiple Myeloma

Developments in the treatment of multiple and smoldering myeloma from ASH 2024

VJHemOnc – Video Journal of Hematology & HemOnc

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022

HealthTree Foundation for Multiple Myeloma

Understanding Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD

HealthTree Foundation for Multiple Myeloma

HealthTree Podcast for Multiple Myeloma: Ola C. Landgren, MSKCC

HealthTree Foundation for Multiple Myeloma

Smoldering myeloma highlights from ASH 2024: the AQUILA study

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Ola Landgren on Combinations in Newly Diagnosed Myeloma

Advancements in Myeloma Precision Medicine | Ola Landgren, MD, PhD

HealthTree Foundation for Multiple Myeloma

Myeloma Crowd Radio: Dr. Ola Landgren, MD, PhD, Memorial Sloan Kettering

HealthTree Foundation for Multiple Myeloma

Dr C. Ola Landgren Highlights Use of Carfilzomib in Newly Diagnosed Patients With MM

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

Meet LLS-funded Researcher: C. Ola Landgren, MD, PhD.

Leukemia & Lymphoma Society

The potential of MRD-adapted treatment in multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc